Massachusetts AI and Technology Center for Connected Care in Aging and Alzheimer's Disease (MAITC): Clinical Translation and Validation Core

马萨诸塞州老龄化和阿尔茨海默病互联护理人工智能和技术中心 (MAITC)：临床转化和验证核心

• 批准号: 10491823
• 负责人: Deepak Ganesan
• 金额: $ 24.11万
• 依托单位: UNIVERSITY OF MASSACHUSETTS AMHERST
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10491823
• 关键词: Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; Biological Sciences; Brain; Caring; Clinical; Cohort Studies; Consult; Consultations; Data Analytics; Databases; Elderly; Enhancement Technology; Home; Hospitals; Individual; Institutes; Longitudinal cohort study; Massachusetts; Monitor; Patient Recruitments; Pilot Projects; Process; Research; Research Design; Research Personnel; Research Project Grants; Resources; Services; Technology; Training; Translations; Validation; Woman; analytical method; base; clinical translation; cohort; connected care; design; feasibility testing; healthy aging; improved; interest; knowledge base; knowledgebase; older patient; programs; recruit; research to practice; rural setting; success; technology validation; urban setting; usability

PROJECT SUMMARY: Clinical Translation & Validation Core The activities of the Clinical Translation and Validation Core will support the pilot project research process for the Massachusetts AI and Technology Center for Connected Care in Aging and Alzheimer's Disease (MAITC) by providing access to state-of-art facilities, consulting services, and intellectual resources to enable validation and feasibility-testing of AI-enhanced technologies. To achieve these objectives, the Clinical Translation and Validation Core will pursue the following three aims. First, it will provide a streamlined validation pipeline for taking promising AI-enhanced technologies from benchtop to real-world deployment to enable at-home use for older adults and patients with AD/ADRD. To accomplish this, the Clinical Translation and Validation Core will leverage state-of-art facilities for technology validation at the UMass Amherst Institute of Applied Life Sciences (IALS) and the Northeastern Consortium on Technology for Proactive Care. The Clinical Translation and Validation Core will also provide pilot project teams the opportunity to recruit participants in both urban and rural settings across Eastern and Western Massachusetts. The Clinical Translation and Validation Core will leverage longitudinal study cohorts already engaged with the Massachusetts Alzheimer’s Disease Research Center (MADRC) and the Harvard Brain Study (HABS), and ad-hoc cohorts at the Brandeis and Brigham Women’s Hospital Roybal Centers and UMass IALS. Second, the Clinical Translation and Validation Core will support the pilot project process by contributing to defining the call for proposals by suggesting AI-enhanced technologies that are suitable for validation by leveraging MIATC resources (in coordination with the Technology Identification and Training Core). It will also provide input regarding the selection of pilots based on technical, usability, and feasibility criteria and offer consulting services and technical support to enhance likelihood of pilot project success. Third, the Clinical Translation and Validation Core will maintain a continually evolving knowledge base of emerging advances in AI-enhanced technologies that have the potential to significantly improve Healthy Aging and AD/ADRD care. This database will summarize the key strengths and weaknesses of these technologies and the types of settings where each technology could be used. The Clinical Translation and Validation Core will also facilitate pairing of technology developers with clinical researchers and other stakeholders with interest in validating AI-enhanced technologies. The activities of the Clinical Translation and Validation Core will increase the impact of the pilot project program by providing teams with resources to bridge the gap between research and implementation in real-world settings.

项目摘要：临床翻译和验证核心 临床翻译和验证核心的活动将支持试点项目研究过程 马萨诸塞州的AI和技术中心衰老和阿尔茨海默氏病（MAITC） 通过提供访问最先进的设施，咨询服务和智力资源以实现验证 以及对AI增强技术的可行性测试。 为了实现这些目标，临床翻译和验证核心将追求以下三个目标。 首先，它将提供一个简化的验证管道，用于从 到现实世界中的台式台面，以便为老年人和AD/ADRD患者提供家庭用途。到 这样做，临床翻译和验证核心将利用技术的最新设施 在UMass Amherst应用生命科学研究所（IALS）和东北财团的验证 积极护理的技术。临床翻译和验证核心还将提供试点项目 团队有机会在东部和西部招募参与者 马萨诸塞州。临床翻译和验证核心将已经利用纵向研究队列 与马萨诸塞州阿尔茨海默氏病研究中心（MADRC）和哈佛大学大脑互动 研究（HAB）和布兰代斯和杨百翰妇女医院皇家中心的临时同伙 UMass IALS。其次，临床翻译和验证核心将通过 通过建议适合AI增强技术来定义提案的呼吁 通过利用MIATC资源来验证（与技术识别和培训协调 核）。它还将根据技术，可用性和可行性提供有关飞行员选择的意见 标准并提供咨询服务和技术支持，以增强试点项目成功的可能性。第三， 临床翻译和验证核心将保持不断发展的新兴知识基础 AI增强技术的进步，这些技术有可能显着改善健康的衰老和 广告/ADRD护理。该数据库将总结这些技术的关键优势和劣势以及 可以使用每种技术的设置类型。临床翻译和验证核心将 还促进了技术开发人员与临床研究人员和其他对 验证AI增强技术。临床翻译和验证核心的活动将增加。 试点项目计划的影响，通过为团队提供资源来弥合研究之间的差距 和现实世界中的实现。